The Traderszone Network

Published in TZ Latest News 6 December, 2021 by The TZ Newswire Staff

Purple Biotech Announces Initiation of Part 2 of Ongoing Phase 1/2 Clinical Trial Evaluating NT219 for Treatment of Multiple Cancers Supporting Potential Expansion of Clinical Program

Part 2 is a Dose Escalation Study of NT219, in Combination with cetuximab (ERBITUX®), in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck Cancer or Colorectal Adenocarcinoma